Role of Serine Proteases and their Inhibitors in Tumor Growth and Angiogenesis

  • A. Noël
  • J.-M. Foidart
Part of the Cancer Metastasis — Biology and Treatment book series (CMBT, volume 4)


Acquisition of invasive/metastatic potential through protease expression is a key event in tumor progression. The proteolytic enzyme plasmin is generated from the precursor plasminogen by the action of urokinase-type plasminogen activator (urokinase, uPA) or tissue-type plasminogen activator (tPA) under the control of plasminogen activator inhibitor-1 or PAI-1. High levels of components of this proteolytic system including uPA, its cell surface receptor (uPAR) and its inhibitor PAI-1 have been correlated with a poor prognosis for different cancers. The initial concept for the implication of serine proteases during cancer progression is that proteases degrade extracellular matrix components, a prerequisite for endothelial, inflammatory or tumor cell migration to distant sites. They have also been implicated in the activation of cytokines or other proteinases, as well as in the release of growth factors sequestered within the extracellular matrix. Recent information have underlined the importance of cell-surface proteases, their receptors/activators or their inhibitors in cell migration. This review focuses on the emerging roles of the plasminogen/plasmin system during cancer growth and angiogenesis with a special emphasis on PAI-1.


Plasminogen Activator Urokinase Plasminogen Activator Urokinase Receptor Plasminogen Activation System Pericellular Proteolysis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Andreasen PA, Kjoller L, Christensen L, Duffy MJ. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 1997; 72: 1–22.CrossRefPubMedGoogle Scholar
  2. Bajou K, Masson V, Gerard RD, Schmitt P, Albert V, Praus M, Lund LR, Frandsen TL, Brunner N, Dano K, Fusenig NE, Weidle UH, Carmeliet G, Loskutoff DJ, Collen D, Carmeliet P, Foidart JM, Noël A. The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin: implications for antiangiogenic strategies. J Cell Biol 2001; 152: 777–784.CrossRefPubMedGoogle Scholar
  3. Bajou K, Noël A, Gerard RD, Masson V, Brunner N, Holst-Hansen C, Skobe M, Fusenig NE, Carmeliet P, Collen D, Foidart JM. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med 1998; 4: 923–928.CrossRefPubMedGoogle Scholar
  4. Bergers G, Brekken R, McMahon GA, Vu TH, Itoh T, Tamaki K, Tanzawa K, Thorpe P, Werb Z, Hanahan D. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000; 2: 737–744.PubMedCrossRefGoogle Scholar
  5. Blasi F. uPA, uPAR, PAI-1: key intersection of proteolytic, adhesive and chemotactic highways? Immunol Today 1997; 18: 415–417.CrossRefPubMedGoogle Scholar
  6. Blasi F. The urokinase receptor. A cell surface, regulated chemokine. APMIS 1999; 107: 96–101.PubMedCrossRefGoogle Scholar
  7. Bouchet C, Spyratos F, Martin PM, Hacene K, Gentile A, Oglobine J. Prognostic value of urokinase-type plasminogen activator and 2 inhibitors PAI-1 and PAI-2 in breast cancer. Bull Cancer 1994; 81: 770–779.PubMedGoogle Scholar
  8. Brunner N, Nielsen HJ, Hamers M, Christensen IJ, Thorlacius-Ussing O, Stephens RW. The urokinase plasminogen activator receptor in blood from healthy individuals and patients with cancer. APMIS 1999; 107: 160–167.PubMedCrossRefGoogle Scholar
  9. Bugge TH, Kombrinck KW, Xiao Q, Holmback K, Daugherty CC, Witte DP, Degen JL. Growth and dissemination of Lewis lung carcinoma in plasminogen-deficient mice. Blood 1997; 90: 4522–4531.PubMedGoogle Scholar
  10. Bugge TH, Lund LR, Kombrinck KK, Nielsen BS, Holmback K, Drew AF, Flick MJ, Witte DP, Dano K, Degen JL. Reduced metastasis of Polyoma virus middle T antigen-induced mammary cancer in plasminogen-deficient mice. Oncogene 1998; 16: 3097–3104.CrossRefPubMedGoogle Scholar
  11. Carmeliet P, Collen D. Development and disease in proteinase-deficient mice: role of the plasminogen, matrix metalloproteinase and coagulation system. Thromb Res 1998; 91: 255–285.CrossRefPubMedGoogle Scholar
  12. Carmeliet P, Moons L, Lijnen R, Baes M, Lemaitre V, Tipping P, Drew A, Eeckhout Y, Shapiro S, Lupu F, Collen D. Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation. Nat Genet 1997; 17: 439–444.CrossRefPubMedGoogle Scholar
  13. Chambers SK, Gertz RE, Ivins CM, Kacinski BM. The significance of urokinase-type plasminogen activator, its inhibitors and its receptor in ascites of patients with epithelial ovarian cancer. Cancer 1995; 75: 1627–1633.PubMedCrossRefGoogle Scholar
  14. Chapman HA. Plasminogen activators, integrins and the coordinated regulation of cell adhesion and migration. Curr Opin Cell Biol 1997; 9: 714–724.CrossRefPubMedGoogle Scholar
  15. Chapman HA, Wei Y, Simon DI, Waltz DA. Role of urokinase receptor and caveolin in regulation of integrin signaling. Thromb Haemost 1999; 82: 291–297.PubMedGoogle Scholar
  16. Dano K, Romer J, Nielsen BS, Bjorn S, Pyke C, Rygaard J, Lund LR. Cancer invasion and tissue remodeling-cooperation of protease systems and cell types. APMIS 1999; 107: 120–127.PubMedCrossRefGoogle Scholar
  17. de Groot FMH, van Berkom LWA, Scheeren HW. Synthesis and biological evaluation of 2′-carbamate-linked and 2′-carbonate-linked prodrugs of paclitaxel: Selective activation by the tumor-associated protease plasmin. J Med Chem 2000; 43: 3093–3102.PubMedCrossRefGoogle Scholar
  18. Deng G, Curriden SA, Wang S, Rosenberg S, Loskutoff DJ. Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J Cell Biol 1996; 134: 1–9.CrossRefGoogle Scholar
  19. Deng G, Waltz DA, Navaneetha R, Drummond RJ, Rosenberg S, Chapman HA. Identification of the urokinase receptor as an adhesion receptor for vitronectin. J Biol Chem 1994; 269: 32380–32388.Google Scholar
  20. Donati MD. Cancer and thrombosis: from phlegmasia alba dolens to transgenic mice. Thromb Haemost 1995; 74: 278–281.PubMedGoogle Scholar
  21. Duffy MJ, O’Grady PDDOLFJLHJ. Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report. Cancer 1988; 62: 351–353.CrossRefGoogle Scholar
  22. Duggan C, Maguire T, McDermott E, O’Higgins N, Fennelly JJ, Duffy MJ. Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer. Int J Cancer 1995; 61: 597–600.PubMedCrossRefGoogle Scholar
  23. Eitzman DT, Krauss JC, Shen T, Cui J, Ginsburg. Lack of plasminogen activator inhibitor-1 effect in a transgenic mouse model of metastatic melanoma. Blood 1996; 87: 4718–4722.PubMedGoogle Scholar
  24. Fazioli F, Resnati M, Sidenius N, Higashimoto Y, Appella E, Blasi F. A urokinase-sensitive region of the human urokinase receptor is responsible for its chemotactic activity. EMBO J 1997; 16: 7279–7286.CrossRefPubMedGoogle Scholar
  25. Fischer K, Lutz V, Wilhelm O, et al. Urokinase induces proliferation of human ovarian cancer cells: characterization of structural elements required for growth factor function. FEBS Lett 1998; 438: 101–105.CrossRefPubMedGoogle Scholar
  26. Foekens JA, Buessecker F, Peters HA, et al. Plasminogen activator inhibitor-2: prognostic relevance in 1012 patients with primary breast cancer. Cancer Res 1995; 55: 1423–1427.PubMedGoogle Scholar
  27. Frankenne F, Noël A, Bajou K, Sounni NE, Goffin F, Masson V, Munaut C, Remacle A, Foidart JM. Molecular interactions involving urokinase plasminogen activator (uPA), its receptor (uPAR) and its inhibitor, plasminogen activator inhibitor-1 (PAI-1), as new targets for tumour therapy. Emerging Therapeutic Targets 1999; 3: 469–481.CrossRefGoogle Scholar
  28. Ganesh S, Sier CF, Griffioen G, et al. Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer. Cancer Res 1994; 54: 4065–4071.PubMedGoogle Scholar
  29. Gately S, Twardowski P, Stack MS, Cundiff DL, Grella D, Castellino FJ, Enghild J, Kwaan HC, Lee F, Kramer RA, Volpert O, Bouck N, Soff GA. The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin. Proc Natl Acad Sci (USA) 1997; 94: 10868–10872.ADSCrossRefGoogle Scholar
  30. Grondahl-Hansen J, Peters HA, van Putten WL, Look MP, Pappot H, Ronne E, Dano K, Klijn JG, Brunner N, Foekens JA. Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer. Clin Cancer Res 1995; 1: 1079–1087.PubMedGoogle Scholar
  31. Gutierrez LS, Schulman A, Brito-Robinson T, Noria F, Ploplis VA, Castellino FJ. Tumor devel-opment is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1. Cancer Res 2000; 60: 5839–5847.PubMedGoogle Scholar
  32. Jaenicke F, Schmitt M, Graeff H. Urokinase-type plasminogen activator antigen and early relapse in breast cancer [letter]. Lancet 1989; 2: 1049.CrossRefGoogle Scholar
  33. Kanse S, Kost C, Wilhelm O andreasen PA, Preissner KT. The urokinase receptor is a major vitronectin-binding protein on endothelial cells. Exp Cell Res 1996; 224: 344–353.CrossRefPubMedGoogle Scholar
  34. Kjoller L, Kanse SM, Kirkegaard T, Rodenburg KW, Ronne E, Goodman SL, Preissner KT, Ossowski L, Andreasen PA. Plasminogen activator inhibitor-1 represses integrin-and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation. Exp Cell Res 1997; 232: 420–429.PubMedCrossRefGoogle Scholar
  35. Knudson BS, Hapel PC, Nachman RL. Plasminogen activator inhibitor is associated with the extracellular matrix of cultured bovine smooth muscle cells. J Clin Invest 1987; 80: 1082–1089.CrossRefGoogle Scholar
  36. Loskutoff DJ, Curriden SA, Hu G, Deng G. Regulation of cell adhesion by PAI-1. APMIS 1999; 107: 54–61.PubMedCrossRefGoogle Scholar
  37. Ma D, Gerard RD, Li XY, Alizadeh H, Niederkorn JY. Inhibition of metastasis of intraocular melanomas by adenovirus-mediated gene transfer of plasminogen activator inhibitor type 1 (PAI-1) in an athymic mouse model. Blood 1997; 90: 2738–2746.PubMedGoogle Scholar
  38. Miyake H, Hara I, Yamanaka K, Gohji K, Arakawa S, Kamidono S. Elevation of serum levels of urokinase-type plasminogen activator and its receptor is associated with disease progression and prognosis in patients with prostate cancer. Prostate 1999; 39: 123–129.CrossRefPubMedGoogle Scholar
  39. Montesano R, Pepper MS, Mohle-Steinlein U, Risau W, Wagner EF, Orci L. Increased proteolytic activity is responsible for the aberrant morphogenetic behavior of endothelial cells expressing the middle T oncogene. Cell 1990; 62: 435–445.CrossRefPubMedGoogle Scholar
  40. Mustjoki S, Alitalo R, Stephens RW, Vaheri A. Blast cell-surface and plasma soluble urokinase receptor in acute leukemia patients: relationship to classification and response to therapy. Thromb Haemost 1999; 81: 705–710.PubMedGoogle Scholar
  41. Mustjoki S, Sidenius N, Sier CF, Blasi F, Elonen E, Alitalo R, Vaheri A. Soluble urokinase receptor levels correlate with number of circulating tumor cells in acute myeloid leukemia and decrease rapidly during chemotherapy. Cancer Res 2000; 60: 7126–7132.PubMedGoogle Scholar
  42. Noël A, Foidart JM. The role of extra-cellular matrix and fibroblasts in breast carcinoma growth in vivo. J Mammary Gland Biol Neoplasia 1998; 3: 215–225.PubMedCrossRefGoogle Scholar
  43. Noël A, Gilles C, Bajou K, Devy L, Kebers F, Lewalle JM, Maquoi E, Munaut C, Remacle A, Foidart JM. Emerging roles for proteinases in cancer. Invasion Metastasis 1997; 17: 221–239.PubMedGoogle Scholar
  44. O’Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88: 277–285.Google Scholar
  45. Ossowski L, Russo-Payne H, Wilson EL. Inhibition of urokinase-type plasminogen activator by antibodies: the effects on dissemination of a human tumor in the nude mouse. Cancer Res 1991; 51: 274–281.PubMedGoogle Scholar
  46. Pappot H, Hoyer-Hansen G, Ronne E, Hoi-Hansen H, Brunner N, Dano K, Grondahl-Hansen J. Elevated levels of receptor for urokinase plasminogen activator in patients with non-small cell lung cancer. Eur J Cancer 1997; 33: 867–872.CrossRefPubMedGoogle Scholar
  47. Pedersen AN, Christensen IJ, Stephens RW, Briand P, Mouridsen H, Dano K. The complex between urokinase and its type-1 inhibitor in primary breast cancer: relation to survival. Cancer Res 2000; 60: 6927–6934.PubMedGoogle Scholar
  48. Pedersen H, Brunner N, Francis D, Osterlind K, Ronne E, Hansen HH, Dano K, Grondahl-Hansen J. Prognostic impact of urokinase, urokinase receptor and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res 1994; 54: 4671–4675.PubMedGoogle Scholar
  49. Praus M, Wauterickx K, Collen D, Gerard RD. Reduction of tumor cell migration and metastasis by adenoviral gene transfer of plasminogen activator inhibitors. Gene Therapy 1999; 6: 236.CrossRefGoogle Scholar
  50. Rabbani SA, Desjardins J, Bell AW, et al. An aminotemial fragment of urokinase isolated from a prostate cancer cell line (PC-3) is mitogenic for osteoblast-like cells. Biochem Biophys Res Commun 1990; 173: 1058–1064.CrossRefPubMedGoogle Scholar
  51. Reuning U, Magdolen V, Wilhelm O, Fischer K, Lutz V, Graeff H, Schmitt M. Multifunctional potential of the plasminogen activation system in tumor invasion and metastasis (review). Int J Oncol 1998; 13: 893–906.PubMedGoogle Scholar
  52. Rifkin DB, Mazzieri R, Munger JS, Noguera I, Sung J. Proteolytic control of growth factor availability. APMIS 1999; 107: 80–85.PubMedCrossRefGoogle Scholar
  53. Schmitt M, Wilhelm O, Reuning U, Kruger A, Harbeck. The urokinase plasminogen activator system as a novel target for tumour therapy. Fibrinolysis & Proteolysis 2000; 14: 114–132.CrossRefGoogle Scholar
  54. Schnaper HW, Barnathan ES, Mazar A, Maheshwari S, Ellis S, Cortez SL, Baricos WH, Kleinman HK. Plasminogen activators augment endothelial cell organization in vitro by two distinct pathways. J Cell Physiol 1995; 165: 107–118.CrossRefPubMedGoogle Scholar
  55. Shapiro RL, Duquette JG, Roses DF, Nunes I, Harris MN, Kamino H, Wilson EL, Rifkin DB. Induction of primary cutaneous melanocytic neoplasms in urokinase-type plasminogen activator (uPA)-deficient and wild-type mice: cellular blue nevi invade but do not progress to malignant melanoma in uPA-deficient animals. Cancer Res 1996; 56: 3597–3604.PubMedGoogle Scholar
  56. Sidenius N, Blasi F. Domain 1 of the urokinase receptor (uPAR) is required for uPAR-mediated cell binding to vitronectin. FEBS Lett 2000; 470: 40–46.CrossRefPubMedGoogle Scholar
  57. Sier CF, Stephens RW, Bizik J, Mariani A, Bassan M, Pedersen N, Frigerio L, Ferrari A, Dano K, Brunner N, Blasi F. The level of urokinase type plasminogen activator receptor is increased in serum of ovarian cancer patients. Cancer Res 1998; 58: 1843–1849.PubMedGoogle Scholar
  58. Simon DI, Wei Y, Zhang L, Rao NK, Xu H, Chen Z, Liu Q, Rosenberg S, Chapman HA. Identification of a urokinase receptor-integrin interaction site. Promiscuous regulator of integrin function. J Biol Chem 2000; 275: 10228–10234.CrossRefPubMedGoogle Scholar
  59. Soff GA, Sanderowitz J, Gately S, Verrusio E, Weiss I, Brem S, Kwaan HC. Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis and metastasis to lung and liver in an athymic mouse model. J Clin Invest 1995; 96, 2593–2600.PubMedCrossRefGoogle Scholar
  60. Stack MS, Gately S, Bafetti LM, Enghild J, Soff GA. Angiostatin inhibitits endothelial and melanoma cellular invasion by blocking matrix-enhanced plasminogen activation. Biochem J 1999; 340: 77–84.CrossRefPubMedGoogle Scholar
  61. Stahl A, Mueller BM. Melanoma cell migration on vitronectin: regulation by components of the plasminogen activation system. Int J Cancer 1997; 71: 116–122.CrossRefPubMedGoogle Scholar
  62. Stefansson S, Lawrence DA. The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin [see comments]. Nature 1996; 383: 441–443.CrossRefADSPubMedGoogle Scholar
  63. Stephens R, Pedersen AN, Nielsen HJ, Hamers M, Hoyer-Hansen G, Ronne E, Dybkjaer E, Dano K, Brunner N. ELISA determination of soluble urokinase receptor in blood from healthy donors and cancer patients. Clin Chem 1997; 43: 1868–1876.PubMedGoogle Scholar
  64. Stephens RW, Brunner N, Janicke F, Schmitt M. The urokinase plasminogen activator system as a target for prognostic studies in breast cancer. Breast Cancer Res Treat 1998; 52: 99–111.CrossRefPubMedGoogle Scholar
  65. Stephens RW, Nielsen HJ, Christensen IJ, Thorlacius-Ussing O, Sorensen S, Dano K, Brunner N. Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis. J Natl Cancer Inst 1999; 91: 869–874.CrossRefPubMedGoogle Scholar
  66. Stephens RW, Tapiovaara HRTBJVA. Alpha2-macroglobulin restricts plasminogen activation to the surface of RC2A leukemia cells. Cell Regul 1991; 2: 1057–1065.PubMedGoogle Scholar
  67. Sugiura Y, Ma L, Sun B, Shimada H, Laug WE, Seeger RC, Declerck YA. The plasminogen-plasminogen activator (PA) system in neuroblastoma: role of PA inhibitor-1 in metastasis. Cancer Res 1999; 59: 1327–1336.PubMedGoogle Scholar
  68. Tarui T, Mazar AP, Cines DB, Takada Y. Urokinase receptor (uPAR/CD87) is a ligand for integrins and mediates cell-cell interaction. J Biol Chem 2001; 276: 3983–3990.PubMedCrossRefGoogle Scholar
  69. Tsuboi R, Rifkin DB. Bimodal relationship between invasion of the amniotic membrane and plasminogen activator activity. Int J Cancer 1990; 46: 56–60.PubMedCrossRefGoogle Scholar
  70. Tressler RJ, Pitot PA, Stratton-Thomas JR, Forrest LD, Zhuo S, Drummond RJ, Fong S, Doyle MV, Doyle LV, Min HY, Rosenberg S. Urokinase receptor antagonists: discovery and application to in vivo models of tumor growth. APMIS 1999; 107: 168–173.PubMedCrossRefGoogle Scholar
  71. Wei Y, Waltz DA, Rao NK, Drummond RJ, Rosenberg S, Chapman HA. Identification of the urokinase receptor as an adhesion receptor for vitronectin. J Biol Chem 1994; 269: 32380–32388.PubMedGoogle Scholar
  72. Yebra M, Goretzki L, Pfeifer M, Mueller BM. Urokinase-type plasminogen activator binding to its receptor stimulates tumor cell migration by enhancing integrin-mediated signal transduction. Exp Cell Res 1999; 250: 231–240.CrossRefPubMedGoogle Scholar
  73. Yu HR, Schultz RM. Relationship between secreted urokinase plasminogen activator activity and metastatic potential in murine B16 cells transfected with human urokinase sense and antisense genes. Cancer Res 1990; 50: 7623–7633.PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 2002

Authors and Affiliations

  • A. Noël
    • 1
  • J.-M. Foidart
    • 1
  1. 1.Laboratory of Tumor and Development BiologyUniversity of LiègeLiègeBelgium

Personalised recommendations